Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine Plus Apatinib vs Vinorelbine in Advanced TNBC
NCT03254654Phase 2Completed
- Sponsor
- Fudan University
- Start
- Aug 2017
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in triple-negative breast cancer (TNBC), sponsored by Fudan University. Started Aug 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03254654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03254654.